BRISBANE, Calif., Dec. 10, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, has received the 2008 Emerging Technology Award for Biotechnology from the Silicon Valley/San Jose Business Journal. BiPar was selected as the first place winner in the biotechnology category for the company's pioneering work with poly (ADP-ribose) polymerase (PARP) inhibitors, a targeted therapeutic approach to treating triple negative breast and other solid tumor cancers by preventing cancer cells from repairing their own damaged DNA.
